Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS)
CUSIP: 00461U105
Q2 2024 13F Holders as of 30 Jun 2024
- Type / Class
- Equity / Common Stock, $0.00001 par value
- Shares outstanding
- 138,752,791
- Total 13F shares
- 52,848,132
- Share change
- -1,336,802
- Total reported value
- $58,129,308
- Put/Call ratio
- 10%
- Price per share
- $1.10
- Number of holders
- 93
- Value change
- -$1,619,597
- Number of buys
- 42
- Number of sells
- 58
Quarterly Holders Quick Answers
What is CUSIP 00461U105?
CUSIP 00461U105 identifies ACRS - Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 00461U105:
Top shareholders of ACRS - Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BML Capital Management, LLC |
13F
|
Company |
6.8%
|
9,395,934
|
$11,650,958 | — | 31 Mar 2024 | |
| BlackRock Finance, Inc. |
13F
|
Company |
3.7%
|
5,202,147
|
$6,450,660 | — | 31 Mar 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
3.6%
|
4,929,775
|
$6,112,921 | — | 31 Mar 2024 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
2.4%
|
3,282,982
|
$4,070,898 | — | 31 Mar 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
2.4%
|
3,273,492
|
$4,059,130 | — | 31 Mar 2024 | |
| Bain Capital Life Sciences Investors, LLC |
13F
|
Company |
2.2%
|
3,000,000
|
$3,720,000 | — | 31 Mar 2024 | |
| Rock Springs Capital Management LP |
13F
|
Company |
2%
|
2,753,495
|
$3,414,334 | — | 31 Mar 2024 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
1.5%
|
2,135,367
|
$2,646,000 | — | 31 Mar 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
1.2%
|
1,673,400
|
$2,075,000 | — | 31 Mar 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.1%
|
1,565,054
|
$1,940,845 | — | 31 Mar 2024 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
1%
|
1,451,100
|
$1,799,364 | — | 31 Mar 2024 | |
| STATE STREET CORP |
13F
|
Company |
0.96%
|
1,338,439
|
$1,659,664 | — | 31 Mar 2024 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.96%
|
1,329,616
|
$1,648,724 | — | 31 Mar 2024 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.87%
|
1,212,260
|
$1,503,202 | — | 31 Mar 2024 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.69%
|
957,021
|
$1,186,706 | — | 31 Mar 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.67%
|
930,003
|
$1,153,203 | — | 31 Mar 2024 | |
| Samsara BioCapital, LLC |
13F
|
Company |
0.5%
|
696,171
|
$863,252 | — | 31 Mar 2024 | |
| GSA CAPITAL PARTNERS LLP |
13F
|
Company |
0.49%
|
679,137
|
$842,000 | — | 31 Mar 2024 | |
| FMR LLC |
13F
|
Company |
0.48%
|
671,828
|
$833,067 | — | 31 Mar 2024 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.44%
|
612,205
|
$759,134 | — | 31 Mar 2024 | |
| Palo Alto Investors LP |
13F
|
Company |
0.41%
|
569,832
|
$706,592 | — | 31 Mar 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.41%
|
562,224
|
$697,157 | — | 31 Mar 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.35%
|
491,666
|
$609,665 | — | 31 Mar 2024 | |
| Acuitas Investments, LLC |
13F
|
Company |
0.33%
|
461,663
|
$572,462 | — | 31 Mar 2024 | |
| Aisling Capital Management LP |
13F
|
Company |
0.31%
|
434,455
|
$538,724 | — | 31 Mar 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.3%
|
419,334
|
$519,974 | — | 31 Mar 2024 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.24%
|
331,740
|
$411,358 | — | 31 Mar 2024 | |
| HighTower Advisors, LLC |
13F
|
Company |
0.23%
|
312,614
|
$386,000 | — | 31 Mar 2024 | |
| STRS OHIO |
13F
|
Company |
0.19%
|
264,700
|
$328,000 | — | 31 Mar 2024 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
0.19%
|
264,377
|
$327,827 | — | 31 Mar 2024 | |
| Man Group plc |
13F
|
Company |
0.18%
|
247,675
|
$307,117 | — | 31 Mar 2024 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.17%
|
241,101
|
$298,965 | — | 31 Mar 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.17%
|
232,771
|
$288,636 | — | 31 Mar 2024 | |
| Mirae Asset Global Investments Co., Ltd. |
13F
|
Company |
0.02%
|
31,552
|
$239,364 | — | 31 Mar 2024 | |
| Frank Ruffo |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
201,883
|
$211,977 | — | 10 Mar 2022 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.12%
|
166,656
|
$206,653 | — | 31 Mar 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.11%
|
145,812
|
$180,807 | — | 31 Mar 2024 | |
| Kamil Ali-Jackson |
3/4/5
|
Chief Legal Officer |
—
class O/S missing
|
160,214
|
$168,225 | — | 03 Jan 2022 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
0.1%
|
133,831
|
$165,950 | — | 31 Mar 2024 | |
| David N. Gordon |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
147,447
|
$154,819 | — | 13 Jul 2021 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.09%
|
123,460
|
$153,090 | — | 31 Mar 2024 | |
| XTX Topco Ltd |
13F
|
Company |
0.09%
|
123,100
|
$152,644 | — | 31 Mar 2024 | |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM |
13F
|
Company |
0.01%
|
18,694
|
$151,234 | — | 31 Mar 2024 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
0.08%
|
109,767
|
$137,000 | — | 31 Mar 2024 | |
| Douglas J. Manion |
3/4/5
|
Pres and CEO, Director |
—
mixed-class rows
|
122,813
mixed-class rows
|
$128,954 | — | 01 Jan 2024 | |
| Connor, Clark & Lunn Investment Management Ltd. |
13F
|
Company |
0.07%
|
100,773
|
$124,959 | — | 31 Mar 2024 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.07%
|
97,220
|
$120,545 | — | 31 Mar 2024 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.06%
|
89,061
|
$110,435 | — | 31 Mar 2024 | |
| Marquette Asset Management, LLC |
13F
|
Company |
0.06%
|
83,979
|
$104,134 | — | 31 Mar 2024 | |
| Deuterium Capital Management, LLC |
13F
|
Company |
0.06%
|
79,993
|
$99,191 | — | 31 Mar 2024 |
Institutional Holders of Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) as of Q2 2024
As of 30 Jun 2024,
Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) was held by
93 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
52,848,132 shares.
The largest 10 holders included
BML Capital Management, LLC, VANGUARD GROUP INC, MILLENNIUM MANAGEMENT LLC, D. E. Shaw & Co., Inc., Rock Springs Capital Management LP, BlackRock Inc., Stonepine Capital Management, LLC, ACADIAN ASSET MANAGEMENT LLC, Trium Capital LLP, and TWO SIGMA ADVISERS, LP.
This page lists
94
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
93
Q2 2024 holders
93
Holder diff
0
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 Value $ | Q2 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.